These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 3474777)
21. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. Katz WA; Alexander S; Bland JH; Blechman W; Bluhm GB; Bonebrake RA; Falbo A; Greenwald RA; Hartman S; Hobbs T; Indenbaum S; Lergier JE; Lanier BG; Lightfoot RW; Phelps P; Sheon RP; Torretti D; Wenger ME; Wilske K J Rheumatol Suppl; 1982; 8():173-8. PubMed ID: 6813481 [TBL] [Abstract][Full Text] [Related]
22. [Gold compounds and D-penicillamine for therapy of rheumatoid arthritis]. Miyamoto S; Inoue T Nihon Rinsho; 1992 Mar; 50(3):515-20. PubMed ID: 1588740 [TBL] [Abstract][Full Text] [Related]
23. Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study. Kvien TK; Høyeraal HM; Sandstad B; Kass E Scand J Rheumatol Suppl; 1986; 63():79-83. PubMed ID: 3474778 [TBL] [Abstract][Full Text] [Related]
24. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Sesin CA; Bingham CO Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659 [TBL] [Abstract][Full Text] [Related]
25. [Long-term therapy with gold salts in rheumatoid arthritis. Review of the literature and personal contribution]. Copertari N; Cordioli E; Martinelli M Minerva Med; 1993 May; 84(5):219-25. PubMed ID: 8316339 [TBL] [Abstract][Full Text] [Related]
26. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365 [TBL] [Abstract][Full Text] [Related]
27. A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate. Hull RG; Morgan SH; Parke AL; Childs L; Goldman M; Hughes GR Int J Clin Pharmacol Res; 1984; 4(6):395-401. PubMed ID: 6442711 [TBL] [Abstract][Full Text] [Related]
28. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739 [TBL] [Abstract][Full Text] [Related]
29. An analysis of worldwide safety experience with auranofin. Heuer MA; Pietrusko RG; Morris RW; Scheffler BJ J Rheumatol; 1985 Aug; 12(4):695-9. PubMed ID: 3932651 [TBL] [Abstract][Full Text] [Related]
30. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132 [TBL] [Abstract][Full Text] [Related]
31. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843 [TBL] [Abstract][Full Text] [Related]
32. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314 [TBL] [Abstract][Full Text] [Related]
33. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Anderson JJ; Bolognese JA; Felson DT Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263 [TBL] [Abstract][Full Text] [Related]
34. [Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents]. Sakurai T; Iso T; Inoue H; Sano K; Takeuchi K; Takagishi K Ryumachi; 2001 Jun; 41(3):635-45. PubMed ID: 11505513 [TBL] [Abstract][Full Text] [Related]
35. Hematuria in patients with rheumatoid arthritis receiving gold and D-penicillamine. Leonard PA; Bienz SR; Clegg DO; Ward JR J Rheumatol; 1987 Feb; 14(1):55-9. PubMed ID: 3106632 [TBL] [Abstract][Full Text] [Related]
36. A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report. Barraclough D; Brook A; Brooks P; Boyden K; Thomas D; Tymms K J Rheumatol Suppl; 1982; 8():197-200. PubMed ID: 6813485 [TBL] [Abstract][Full Text] [Related]
37. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Welsing PM; Fransen J; van Riel PL Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762 [TBL] [Abstract][Full Text] [Related]
38. [An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis]. Kawanaka N; Yamamura M; Hashimoto H; Okamoto H; Morita Y; Kawashima M; Aita T; Okamoto A; Makino H Ryumachi; 1998 Dec; 38(6):801-9. PubMed ID: 10047718 [TBL] [Abstract][Full Text] [Related]
39. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443 [TBL] [Abstract][Full Text] [Related]
40. [Effectiveness and limits of D-penicillamine therapy]. Behrend T; Eisterhues C; Behrend M Z Rheumatol; 1988; 47 Suppl 1():28-33. PubMed ID: 3213269 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]